BMYMP News and Press, Bristol-Myers Squibb $2Pr From 08/04/22

Pfizer will have an outstanding 2022. 2023 will be a strong year as well. But there's not a lot of long-term growth to be expected - instead, revenue at the end of the current decade will most likely be meaningfully lower compared to 2022. Shares aren't expensive, but they aren't ...

Bristol-Myers Squibb Company (BMY) Q2 2022 Earnings Conference Call July 27, 2022 08:00 AM ET Company Participants Tim Power - Vice President, Investor Relations Giovanni Caforio - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer ...

The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2022 Q2 earnings call. For further details see: Bristol-Myers Squibb Company 2022 Q2 - Results - Earnings Call Presentation

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The Dividend Champions list is a monthly...

Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended June 30, 2022, Baron Health Care Fund declined 10.00% compared with the Benchmark. We are partic...

Biotechnology/Pharmaceuticals and Healthcare providers are undervalued relative to historical averages. Healthcare equipment is the most overvalued subsector. Fast facts on IYH. This monthly article series shows a dashboard with aggregate industry metrics in healthcare. ...

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summarizes Q2 of 2022, where the most p...

Comparing today to the year 2000. How much further downside should we expect in stocks? What is likely to unfold on the economic front? What areas of capital markets present upside opportunity? Last year we partied like it was 1999. It was an epic party to be sur...

The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names. It's clear (to us) that AUPH should be on the ...